Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,045 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Navarra SV, et al. Among authors: thomas m. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4. Lancet. 2011. PMID: 21296403 Clinical Trial.
Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D. van Vollenhoven RF, et al. Among authors: thomas m. Rheumatology (Oxford). 2020 Feb 1;59(2):281-291. doi: 10.1093/rheumatology/kez279. Rheumatology (Oxford). 2020. PMID: 31302695 Free PMC article. Clinical Trial.
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups. Wallace DJ, et al. Among authors: thomas m. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4. Lupus. 2013. PMID: 23213069 Clinical Trial.
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. Stohl W, et al. Among authors: thomas m. Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400. Arthritis Rheum. 2012. PMID: 22275291 Free PMC article. Clinical Trial.
A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study. Furie RA, et al. Among authors: thomas m. Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19. Ann Rheum Dis. 2015. PMID: 24748629 Clinical Trial.
A multi-centre UK-based survey on angioedema secondary to acquired C1 inhibitor deficiency.
Morsi H, Huissoon A, Grammatikos A, Whyte A, Manson A, Ekbote A, Sivadasan A, Boulton APR, Herwadkar A, Anantharachagan A, Price A, Steele C, Stroud C, Chopra C, Arnold D, Eren E, Cleave E, Drewe E, Moon E, Zinser E, Hayman G, Alachkar H, Ghanta H, Bourne H, Abdelhakam I, Dempster J, Townsend K, Sooriyakumar K, Lorenzo L, Dziadzio M, Ahuja M, Prasinou M, Frleta-Gilchrist M, Zhang M, Thomas M, Vijayadurai P, Vaitla PM, Sargur R, Herriot R, Yellon RL, Murng SHK, Drinkwater S, Denness S, Denman S, Elkhalifa S, Savic S, Kiani-Alikhan S, Coulter TI, El-Shanawany T, Rahman T, Garcez T, Yong PFK, Jain R. Morsi H, et al. Among authors: thomas m. Clin Exp Immunol. 2025 Jan 4:uxae121. doi: 10.1093/cei/uxae121. Online ahead of print. Clin Exp Immunol. 2025. PMID: 39756409
Comparative species delimitation of a biological conservation icon.
Ghezelayagh A, Simmons JW, Wood JE, Yamashita T, Thomas MR, Blanton RE, Orr OD, MacGuigan DJ, Kim D, Benavides E, Keck BP, Harrington RC, Near TJ. Ghezelayagh A, et al. Among authors: thomas mr. Curr Biol. 2024 Dec 21:S0960-9822(24)01593-8. doi: 10.1016/j.cub.2024.11.053. Online ahead of print. Curr Biol. 2024. PMID: 39755118
Genomic Data and Privacy.
Myers CT, Kumar RD, Pilgram L, Bonomi L, Thomas M, Griffith OL, Fullerton SM, Gibbs RA. Myers CT, et al. Among authors: thomas m. Clin Chem. 2025 Jan 3;71(1):10-17. doi: 10.1093/clinchem/hvae184. Clin Chem. 2025. PMID: 39749498 No abstract available.
11,045 results
You have reached the last available page of results. Please see the User Guide for more information.